Source comparison
Tesamorelin + Ipamorelin Blend FDA Approved Status: Regulatory Comparison
Tesamorelin (Egrifta) FDA-approved (2010) Reduction of excess abdominal fat in HIV-associated lipodystrophy Off-label if used outside approved indication; compounded versions are not FDA-approved finished products Ipamorelin Not FDA-approved None. Investigated
This comparison does not assign a generated winner or score.
- Tesamorelin (Egrifta)
- FDA-approved (2010)
- Reduction of excess abdominal fat in HIV-associated lipodystrophy
- Off-label if used outside approved indication; compounded versions are not FDA-approved finished products
- Ipamorelin
- Not FDA-approved
- None. Investigated in Phase II trials for postoperative ileus and frailty, development discontinued
- Investigational new drug (IND); available for research under compounding exemption
- Tesamorelin + Ipamorelin Blend
- None
- Unapproved compounded combination; available strictly for research purposes under 503B or institutional compounding protocols